Ascletis Showcases Innovative ASC47 Weight Loss Drug Research at European Congress on Obesity

Ascletis Highlights Breakthroughs in Obesity Treatment with ASC47

Ascletis Pharma Inc. is proud to announce its participation in the 32nd European Congress on Obesity (ECO 2025) in Malaga, Spain, showcasing its promising weight loss drug candidate, ASC47. This innovative treatment is specifically designed to target adipose tissue while preserving muscle mass, addressing a critical need in obesity management.

Key Presentations at ECO 2025

Oral Presentation on ASC47

The oral presentation titled "ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity" is scheduled for May 13, 2025, during the session on novel drugs. The presentation, led by Dr. Jinzi Jason Wu, will provide in-depth insights into the preliminary studies of ASC47, including significant weight loss results and its unique muscle-preserving properties, as demonstrated in diet-induced obesity (DIO) mice.

Poster Presentation Details

Additionally, a guided poster presentation titled "ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study" will also be featured by Dr. Wu. This poster will delve into phase Ib studies that evaluate ASC47's effects in healthy individuals, scheduled for the evening session on the same day.

Understanding ASC47

ASC47 is a groundbreaking small molecule agonist that selectively targets the thyroid hormone receptor beta (THRβ). Its unique, ultra-long-acting formulation is administered via subcutaneous injection, allowing it to achieve high concentrations specifically within adipose tissue. This innovative approach promises enhanced efficacy in promoting weight loss while maintaining crucial muscle mass, which is often compromised in traditional weight-loss strategies.

Recently, topline data from the phase Ib trials conducted in Australia demonstrated ASC47's potential in participants with elevated low-density lipoprotein cholesterol (LDL-C). The encouraging results have led to the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the concurrent use of ASC47 with semaglutide in obesity treatment.

The Importance of ECO 2025

The European Congress on Obesity, organized by the European Association for the Study of Obesity (EASO), is a premier event that unites professionals from diverse fields related to obesity research and management. Celebrated annually since 1986, ECO 2025 is expected to attract experts and stakeholders dedicated to advancing obesity treatment, prevention, and research.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a biotechnology firm specializing in research and development across various metabolic diseases. Listed on the Hong Kong Stock Exchange (stock code: 1672.HK), Ascletis is committed to addressing unmet medical needs through innovative drug development. The company's dedicated team is focused on enhancing treatment options available for patients struggling with metabolic disorders.

For more detailed information on Ascletis and its current research initiatives, visit their official website at Ascletis.com. For inquiries related to this press release, contact Peter Vozzo at ICR Healthcare, or the Ascletis PR and IR teams directly.

As this revolutionary drug candidate continues to progress through the clinical pipeline, the medical community eagerly anticipates the future of obesity treatment and the potential impact of ASC47 on patient care internationally.